| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/23/2007 | CA2332188C 5-(1-aminocyclohexyl)-2(1h)-pyridinone compounds and intermediates in the production thereof |
| 01/23/2007 | CA2331288C Aqueous process for manufacturing paroxetine solid dispersions |
| 01/23/2007 | CA2260037C Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| 01/23/2007 | CA2191747C (a)-annelated pyrrole derivatives and pharmaceutical use thereof |
| 01/23/2007 | CA2164296C Heterocyclic chemistry |
| 01/18/2007 | WO2007009044A2 Inhibitors of egln3 activity for the treatment of neurodegenerative disorders |
| 01/18/2007 | WO2007008317A2 Process for preparation of sertraline hydrochloride form i |
| 01/18/2007 | WO2007007919A2 Heterocyclic janus kinase 3 inhibitors |
| 01/18/2007 | WO2007007909A1 Combination drug containing diaryl-substituted 5-membered heterocyclic derivative |
| 01/18/2007 | WO2007007890A1 N-dihydroxyalkyl-substituted 2-oxoimidazole derivative |
| 01/18/2007 | WO2007007787A1 Non-human gene-disrupted animal having adam11 gene disruption |
| 01/18/2007 | WO2007007778A1 Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| 01/18/2007 | WO2007007688A1 3,5-diamino-1,2,4-triazole derivative |
| 01/18/2007 | WO2007007588A1 Compound having cyclic group with planarity as core |
| 01/18/2007 | WO2007007133A2 Composition for treatment of psychosis |
| 01/18/2007 | WO2007007132A1 Aripiprazole salts |
| 01/18/2007 | WO2007007105A1 Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease |
| 01/18/2007 | WO2007007072A1 5-htx modulators |
| 01/18/2007 | WO2007006942A1 Thiazole derivatives for the treatment of dyskinesias caused by a chemical treatment |
| 01/18/2007 | WO2007006941A1 Thiazole derivatives for the treatment of restless legs syndrome |
| 01/18/2007 | WO2007006928A1 N-[(4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use |
| 01/18/2007 | WO2007006732A1 Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) |
| 01/18/2007 | WO2007006677A1 Benzimidazole derivatives as 5-ht6,5-ht24 |
| 01/18/2007 | WO2007006566A1 Pyridazine compounds as glycogen synthase kinase 3 inhibitors |
| 01/18/2007 | WO2007006547A1 Amide derivatives as kinase inhibitors |
| 01/18/2007 | WO2007006492A1 Use of extracts and constituents of leontopodium as enhancers of cholinergic function |
| 01/18/2007 | WO2007006212A1 Tetrahydroprotoberberine compounds, the synthetic method and the use thereof |
| 01/18/2007 | WO2007006157A1 Neuroprotective modulation of nmda receptor subtype activities |
| 01/18/2007 | WO2007006117A1 Novel cyp2a6 inhibitors |
| 01/18/2007 | WO2006131953A3 Antibodies directed against the myelin basic protein recognising an epitope of cd64 and their use as immunosuppressants |
| 01/18/2007 | WO2006124713A3 4-biarylyl-1-phenylazetidin-2-ones |
| 01/18/2007 | WO2006113140A3 Novel compounds useful for bradykinin b1 receptor antagonism |
| 01/18/2007 | WO2006102596A3 Dosage regimen for the treatment of a traumatic brain injury with progesterone |
| 01/18/2007 | WO2006096780A3 Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
| 01/18/2007 | WO2006096415A3 Modulation of neurodegenerative diseases through the estrogen receptor |
| 01/18/2007 | WO2006058294A3 Modulators of muscarinic receptors |
| 01/18/2007 | WO2006014381A3 Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies |
| 01/18/2007 | WO2006010967A8 Kynurenic acid amide derivatives as nr2b receptor antagonists |
| 01/18/2007 | WO2005097192A9 Active substance combination of a carbinol compound and an opioid |
| 01/18/2007 | US20070015820 1,3-Diacetyl-8-hydroxy-2-(7-hydroxychromanon-3-yl)-9H-xanthen-9-ones; obtained from a culture of the Penicillium strain SPF-3059; prevents growth cone collapse |
| 01/18/2007 | US20070015819 Novel compounds |
| 01/18/2007 | US20070015800 Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith |
| 01/18/2007 | US20070015766 Quinoline Derivatives as NK-3 and NK-2 Antagonists |
| 01/18/2007 | US20070015755 Novel compounds and compositions as protease inhibitors |
| 01/18/2007 | US20070015737 Compounds for inhibiting diseases and preparing cells for transplantation |
| 01/18/2007 | US20070015732 Adenosine receptor antagonists and methods of making and using the same |
| 01/18/2007 | US20070015688 Method for screening for inhibitors of alzheimer's disease |
| 01/18/2007 | US20070015257 Alpha-MSH related compounds and methods of use |
| 01/18/2007 | US20070015217 Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease |
| 01/18/2007 | US20070015202 Atlastin |
| 01/18/2007 | US20070014877 Use of extracts from pelargonium species |
| 01/18/2007 | US20070014840 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription |
| 01/18/2007 | US20070014816 such as a botulinum toxin; pain is not associated with a headache pain |
| 01/18/2007 | US20070014737 Administering quinine, chlorzoxazone, cyclobenzaprine, carisoprodol via vaporization |
| 01/18/2007 | CA2615291A1 Heterocyclic janus kinase 3 inhibitors |
| 01/18/2007 | CA2615147A1 Neuroprotective modulation of nmda receptor subtype activities |
| 01/18/2007 | CA2615129A1 Carbamate compounds for use in treating neurodegenerative disorders |
| 01/18/2007 | CA2615127A1 Methods of treating epileptogenesis |
| 01/18/2007 | CA2615077A1 Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptoms of huntington's disease |
| 01/18/2007 | CA2615007A1 Benzimidazole derivatives as 5-ht6,5-ht24 |
| 01/18/2007 | CA2614834A1 Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist |
| 01/18/2007 | CA2614688A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| 01/18/2007 | CA2614528A1 Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) |
| 01/18/2007 | CA2614385A1 Pyridazine compounds as glycogen synthase kinase 3 inhibitors |
| 01/18/2007 | CA2614147A1 Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| 01/18/2007 | CA2614121A1 Thiazole derivatives for the treatment of dyskinesias caused by a chemical treatment |
| 01/18/2007 | CA2614000A1 Novel 1h-indole-pyridinecarboxamide and 1h-indole- piperidinecarboxamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/17/2007 | EP1743945A1 Screening method |
| 01/17/2007 | EP1743903A2 Methods and compositions for treating disorders involving excitotoxicity |
| 01/17/2007 | EP1743894A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments |
| 01/17/2007 | EP1743891A1 Heterocyclic compounds and methods for modulating CXCR3 function |
| 01/17/2007 | EP1743890A1 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
| 01/17/2007 | EP1743886A1 Method of inhibiting neurotrophin-receptor binding |
| 01/17/2007 | EP1743884A1 Progrugs to d-prolines |
| 01/17/2007 | EP1743645A1 Adhesive patch |
| 01/17/2007 | EP1743640A1 Use of substituted pyrazoline compounds for the preparation of paediatric medicaments |
| 01/17/2007 | EP1743633A1 Sleep-improving composition |
| 01/17/2007 | EP1743631A2 Use of an amphetamine composition for regulating memory consolidation |
| 01/17/2007 | EP1742960A2 Crystalline and amorphous forms of smilagenin |
| 01/17/2007 | EP1742944A1 Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| 01/17/2007 | EP1742940A1 N-[6-(4-morpholinyl)-3-pyridinyl]-2-(tetrahydro-2h-pyran-4-yl)-n-[(1-{[phenyl]methyl}-4-piperidinyl)methyl] acetamide derivatives and related compounds as glyt1 transport inhibitors for the treatment of neurological disorders such as schizophrenia |
| 01/17/2007 | EP1742916A1 Phenyl compounds and their use in the treatment of conditions mediated by the action of pge2 at the ep1 receptor |
| 01/17/2007 | EP1742904A2 Substituted enaminones, their derivatives and uses thereof |
| 01/17/2007 | EP1742707A2 Treatment of cns disorders using cns target modulators |
| 01/17/2007 | EP1742660A2 Treatment of disorders |
| 01/17/2007 | EP1742639A2 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| 01/17/2007 | EP1742634A1 Polycyclic pyrimidines as potassium ion channel modulators |
| 01/17/2007 | EP1742632A2 Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds |
| 01/17/2007 | EP1742629A2 Methods for treating alcoholism |
| 01/17/2007 | EP1742624A2 Dopamine-agonist combination therapy with sedatives for improving sleep quality |
| 01/17/2007 | EP1603914B1 Compounds having activity at 5ht2c receptor and uses thereof |
| 01/17/2007 | EP1537110B1 Triazospiro compounds having nociceptin receptor affinity |
| 01/17/2007 | EP1532148B1 Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity |
| 01/17/2007 | EP1392309B1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
| 01/17/2007 | EP1370259B1 Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 01/17/2007 | EP1341793B1 Crf receptor antagonists and methods relating thereto |
| 01/17/2007 | EP1341531B1 Lactam compound to inhibit beta-amyloid peptide release or synthesis |
| 01/17/2007 | EP1335646B1 Transgenic or recombinant non-human mammals for stop protein and their uses in screening psycho-active medicines |
| 01/17/2007 | EP1301539B1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 01/17/2007 | EP1283047B1 Method for producing a bioactive substance from blood serum |